- Rentschler Biopharma plans to build a new 34,000-square-metre buffer media station at its Laupheim headquarters, aiming to increase production efficiency and site modernisation.
- Construction is scheduled to start in spring 2025, with operations expected by 2028.
Rentschler Biopharma SE, a global contract development and manufacturing organisation (CDMO) specialising in biopharmaceuticals, has announced the construction of a new buffer media station at its headquarters in Laupheim, Germany. The new, four-storey facility, covering 34,000 square metres, is designed to enhance production efficiency and support the company’s environmental goals.
Scheduled to begin construction in spring 2025, the new buffer media station will include dedicated areas for buffer and media preparation, with three media tanks and six buffer tanks for capacity. Designed to integrate with existing infrastructure, the facility will also feature ergonomic workspaces for employees and advanced automation systems to uphold hygiene and safety standards.
Benedikt von Braunmühl, CEO of Rentschler Biopharma, commented, “This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape… While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.”
The facility is expected to be fully operational by 2028, with a focus on meeting rising client demand and supporting global therapeutic availability. Christiane Bardroff, COO, added, “With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands.”